10.10.22
Schrödinger, a computational technology has entered a drug design collaboration with Eli Lilly.
Schrödinger will receive as much as $425 million in discovery, development and commercial milestone payments and will be responsible for the discovery and optimization of small molecule compounds addressing an undisclosed target.
Once complete, Lilly will then be responsible for the completion of preclinical development, clinical development and commercialization. Lilly will participate in the early stages of development, including working with animal models to help characterize compounds. Schrödinger will also be eligible to receive royalties on any asset that becomes commercialized.
Schrödinger will receive as much as $425 million in discovery, development and commercial milestone payments and will be responsible for the discovery and optimization of small molecule compounds addressing an undisclosed target.
Once complete, Lilly will then be responsible for the completion of preclinical development, clinical development and commercialization. Lilly will participate in the early stages of development, including working with animal models to help characterize compounds. Schrödinger will also be eligible to receive royalties on any asset that becomes commercialized.
